Eli Lilly will next month extend the eligibility criteria for its LillyDirect service “to a broader range of healthcare companies”, it announced today.
Following LillyDirect’s UK launch in June, the Mounjaro manufacturer said the service will now be available to “UK pharmacies running private weight management services regulated by the General Pharmaceutical Council (GPhC) or Pharmaceutical Society of Northern Ireland (PSNI)”.
LillyDirect was previously supported by just two dispensing partners in the UK, Pharmacy2U and Onescript.
Read more: Eli Lilly’s dispensing and delivery service LillyDirect comes to UK
Lilly UK & Northern Europe vice president of cardiometabolic health Khalil Asmar said the company is “pleased to be able to extend eligibility for LillyDirect in the UK, as part of our phased approach to ensure that we can successfully scale the service”.
“The aim of LillyDirect is to offer a new option for private UK regulated healthcare companies to support their patients with dispensing and delivery of Lilly medication,” he added.
And Lilly said the “healthcare professional at the private healthcare company retains discretion and ultimate responsibility for all prescribing decisions”, as well as for the “patient-clinician relationship”.
Read more: Retatrutide trials show promise for treating obesity-related conditions
It comes after the Independent Pharmacy Contractors Network launched a “national campaign” to support pharmacies challenging “disputed clawback demands” made under Eli Lilly’s Mounjaro rebate scheme.
And it follows Lilly’s investigational weight loss drug retatrutide showing “meaningful improvements” across common obesity-related conditions in phase 3 trials last month.
